Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Clear Filters

Search Clinical Trials

103 Results
Terminated
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
To participate in this transplant, the patient will need to have a central line. Before the transplant we will test the blood for viruses which can cause problems after the …
Baylor Role: Lead Sponsor
Withdrawn
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)
While patients with nasopharyngeal carcinoma (NPC) may be cured by chemotherapy and radiotherapy, the outlook for patients who are resistant to this treatment or who relapse is poor. Almost all …
Baylor Role: Lead Sponsor
Terminated
Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)
Approximately 10,000 spinal cord injuries (SCI) occur each year, most of which occur in males (80%). Many of these patients develop neurogenic bladder dysfunction (NGB) characterized by overactivity of the …
Baylor Role: Lead Sponsor
Completed
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Participation in this protocol will last about 1 year. To participate in this study, the patient will need to have undergone a stem cell transplant. Before the treatment starts, investigators …
Baylor Role: Lead Sponsor
Terminated
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Allogeneic stem cell transplantation with high-dose chemotherapy affords a better chance of cure of malignant and non-malignant hematological diseases compared to autologous transplantation, because of the lack of stem cell …
Baylor Role: Lead Sponsor
Withdrawn
Rituximab for GVHD
Acute graft-versus-host disease (aGVHD), one of the most important complications of allogeneic hematopoietic stem cell transplantation (HSCT) is associated with significant morbidity and mortality. Grades II to IV aGVHD occur …
Baylor Role: Lead Sponsor
Completed
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells
Previously, some of the cancer cells taken from the patients body were separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was put …
Baylor Role: Lead Sponsor
Completed
Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study
This is a study to compare orally dissolving levodopa (Parcopa) to the conventional immediate release oral levodopa. This is a single-dose, double-blind, placebo controlled crossover trial in participants with Parkinson …
Baylor Role: Lead Sponsor
Completed
Erythropoetin Neuroprotection for Neonatal Cardiac Surgery
Hypothesis: Erythropoetin (EPO) will protect the neonatal brain in the perioperative period for congenital heart surgery. Using a prospective, randomized, placebo-controlled, double-blinded design, the specific aims of this study are: …
Baylor Role: Lead Sponsor
Terminated
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
Infusions of CD45 MAbs A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used 40, 400ug/kg …
Baylor Role: Lead Sponsor